Danish pharmaceutical company Novo Nordisk A/S (NVO) said that it raised its full-year sales and operating profit outlook at constant exchange rates.
For 2020, the company now expects both operating profit and sales growth to be 5%-8% at constant exchange rates. Earlier, the company expected annual operating profit growth to be 2% to 5%, and sales growth of 3% to 6% at CER.
In the third quarter of 2020, the company's sales increased by 7% and operating profit increased by 7%, both at constant exchange rates, reflecting lower than anticipated negative impacts from COVID-19 as well as underlying market demand. Sales growth was positively impacted by inventory changes at wholesaler level in the US.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.